The US Food and Drug Administration issued 510(k) clearance and a CLIA waiver for Diasorin’s four‑plex molecular assay on the new LIAISON Nes platform, enabling detection and differentiation of Influenza A/B, RSV and SARS‑CoV‑2 near the patient. Diasorin said the Liaison Nes delivers lab‑quality PCR results in about 15 minutes and was developed with a major US pharmacy chain partner. Diasorin’s approval marks its formal entry into molecular point‑of‑care testing and expands competition in rapid respiratory diagnostics. The company plans additional infectious‑disease assays for the platform to broaden its POC menu. Regulators and health systems focused on triage and outpatient testing will watch deployment closely; a CLIA waiver removes the need for specialized lab personnel and could accelerate uptake in retail clinics and pharmacies.